Infield Minerals Corp. (TSXV:IN)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.95M -10.3% |
| Revenue (ttm) | n/a |
| Net Income | -340.10K |
| EPS | -0.01 |
| Shares Out | 48.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Average Volume | 77,784 |
| Open | 0.0400 |
| Previous Close | 0.0400 |
| Day's Range | 0.0400 - 0.0400 |
| 52-Week Range | 0.0200 - 0.0650 |
| Beta | 1.05 |
| RSI | 46.39 |
| Earnings Date | Apr 24, 2026 |
About Infield Minerals
Infield Minerals Corp. engages in the acquisition, exploration, and evaluation of mineral resource properties in the United States. The company explores for gold and silver deposits. It also holds 100% interest in the Desperado property that consist of 80 lode mining claims covering an area of approximately 1,650 acres located in the Nye County, Nevada; and Kings Canyon property in the state of Utah. Additionally, it has an option agreement to acquire 100% interest in the Detroit sediment hosted gold property in Utah. Infield Minerals Corp. is ... [Read more]
Financial Performance
Financial StatementsNews
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin...
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals (INM) Advances Alzheimer's Research with New Preclinical Data
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimen...
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Pharmaceuticals (INM) Sets 2026 Development Goals
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027 Vanc...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of diseas...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing...
InMed Announces Results of 2025 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
Shares of NVIDIA Corp (NASDAQ: NVDA) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and issued a strong revenue forecast for the cu...
What's Driving InMed's (INM) 22% After-Hours Surge?
InMed Pharmaceuticals Inc. (NASDAQ: INM) shares rose 21.98% in after-hours trading Wednesday, reaching $1.50. Check out the current price of INM stock here . The stock closed Wednesday's regular sess...
InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success
InMed Pharmaceuticals (INM) Achieves Milestone with INM-901 Study Success
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vanc...
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-rel...
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025
VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of propri...
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc....
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to...
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...